Who owns Zentalis Pharmaceuticals, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ZNTL from SEC Form 13F filings across 126 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 126 institutions disclosed 60.5M shares of Zentalis Pharmaceuticals, Inc. worth $167.3M — about 71.5% of shares outstanding; the largest disclosed holder is Squadron Capital Management LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
126
13F holders
$167.3M
value, 2026 filers
71.5%
of shares outstanding (60.5M sh)
26
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ZNTL's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Squadron Capital Management LLC | 6.8M | $18.9M | 4.7% | 8.1% | +84.5% |
| 2 | CITADEL ADVISORS LLC | 4.5M | $12.4M | 0.0% | 5.3% | +95.3% |
| 3 | 5AM Venture Management, LLC | 3.9M | $10.9M | 3.7% | 4.7% | 0.0% |
| 4 | BlackRock, Inc. | 3.9M | $10.8M | 0.0% | 4.6% | +4.2% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3.5M | $9.8M | 0.0% | 4.2% | +24.3% |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 3.1M | $8.5M | 0.0% | 3.6% | +14.0% |
| 7 | TWO SIGMA INVESTMENTS, LP | 2.8M | $7.8M | 0.0% | 3.3% | -7.4% |
| 8 | Patient Square Capital LPNEW | 2.0M | $5.6M | 0.9% | 2.4% | new |
| 9 | Seven Fleet Capital Management LP | 1.5M | $4.2M | 0.8% | 1.8% | +373.6% |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 1.5M | $4.2M | 0.0% | 1.8% | -6.9% |
| 11 | Opaleye Management Inc. | 1.4M | $3.9M | 0.4% | 1.7% | 0.0% |
| 12 | Decheng Capital LLC | 1.3M | $3.7M | 0.5% | 1.6% | 0.0% |
| 13 | ORBIMED ADVISORS LLC | 1.3M | $3.6M | 0.1% | 1.6% | -5.4% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $3.6M | 0.0% | 1.5% | +0.2% |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3M | $3.5M | 0.0% | 1.5% | +57.3% |
| 16 | Qube Research & Technologies Ltd | 1.1M | $3.1M | 0.0% | 1.3% | +97.5% |
| 17 | STATE STREET CORP | 1.1M | $3.1M | 0.0% | 1.3% | +25.1% |
| 18 | BANK OF AMERICA CORP /DE/ | 1.1M | $3.1M | 0.0% | 1.3% | -0.9% |
| 19 | Ishara Investments LP | 1.1M | $3.0M | 2.5% | 1.3% | +5.4% |
| 20 | Boxer Capital Management, LLCNEW | 1.0M | $2.8M | 0.2% | 1.2% | new |
| 21 | PRIMECAP MANAGEMENT CO/CA/ | 957,420 | $2.7M | 0.0% | 1.1% | 0.0% |
| 22 | Pfizer Inc | 953,834 | $2.6M | 1.6% | 1.1% | 0.0% |
| 23 | JPMORGAN CHASE & CO | 951,147 | $2.6M | 0.0% | 1.1% | +4138.8% |
| 24 | AMERIPRISE FINANCIAL INCNEW | 770,397 | $2.1M | 0.0% | 0.9% | new |
| 25 | Soleus Capital Management, L.P. | 706,280 | $2.0M | 0.1% | 0.8% | -25.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.